Выпуск
Pharmaceutical Executive Daily: FDA Approves Tecentriq
Pharmaceutical Executive · 9 октября 2026 г. · 2 мин
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.